116 filings
8-K
MGNX
Macrogenics Inc
3 Apr 24
Other Events
5:24pm
8-K
MGNX
Macrogenics Inc
7 Mar 24
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
4:04pm
8-K
MGNX
Macrogenics Inc
6 Nov 23
MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results
4:04pm
8-K
MGNX
Macrogenics Inc
22 Sep 23
Termination of a Material Definitive Agreement
4:42pm
8-K
MGNX
Macrogenics Inc
9 Aug 23
MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results
4:04pm
8-K
vmuo 3i91rpx38u4
2 Jun 23
Submission of Matters to a Vote of Security Holders
8:39am
8-K
5e4ujqsjp
9 May 23
MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results
4:05pm
8-K
38ztz1rc2odq1wu
24 Mar 23
Other Events
4:33pm
8-K
daic6mmnla
15 Mar 23
MacroGenics Provides Corporate Update and 2022 Financial Results
4:03pm
8-K
akuu2i
10 Mar 23
Regulation FD Disclosure
4:38pm
8-K
qlkgywx3pkr 3o
9 Mar 23
MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million
8:01am
8-K
ggieg4rahz8py2zifweo
13 Feb 23
Other Events
6:12pm
8-K
p1bq4ok41my 8b
5 Jan 23
MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors
8:28am
8-K
2wkweu57z7jurh bikwn
21 Dec 22
Departure of Directors or Certain Officers
4:09pm
8-K
uv9892 c13l1myoi
16 Dec 22
Entry into a Material Definitive Agreement
4:28pm
8-K
qx6557ffpkdxi
17 Nov 22
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
6:42pm
8-K
910g vky5q
3 Nov 22
MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results
4:02pm
8-K
53i5p 16l5nv
17 Oct 22
Entry into a Material Definitive Agreement
4:22pm
8-K
m5wiyoybz fk9bhfo6p9
8 Aug 22
MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results
4:03pm
8-K
qrn96r064h ur1c2dan
8 Jul 22
MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer
5:01pm